# Specified Drug-use Survey of the Granular Capsule Formulation of Omega-3 Fatty Acid Ethyl Esters: OCEAN3

> **NCT02285166** · — · COMPLETED · sponsor: **Takeda** · enrollment: 15330 (actual)

## Conditions studied

- Hyperlipidemia

## Interventions

- **DRUG:** Omega-3 fatty acid ethyl esters
- **DRUG:** Standard antihyperlipidemic therapy other than administration of omega-3 fatty acid ethyl esters (Lotriga).

## Key facts

- **NCT ID:** NCT02285166
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-21
- **Primary completion:** 2020-07-14
- **Final completion:** 2020-07-14
- **Target enrollment:** 15330 (ACTUAL)
- **Last updated:** 2022-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02285166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02285166, "Specified Drug-use Survey of the Granular Capsule Formulation of Omega-3 Fatty Acid Ethyl Esters: OCEAN3". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02285166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*